Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Domperidone, a new dopamine antagonist.

M C Champion, M Hartnett, M Yen

    CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
    |September 1, 1986
    PubMed
    Summary

    Domperidone, a new dopamine antagonist in Canada, effectively manages upper gastrointestinal motility disorders and prevents Parkinson's disease medication side effects. It acts as an antiemetic and prokinetic agent with a favorable safety profile.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization.

    Clinical pharmacology and therapeutics·2017
    Same author

    Effect of family caregiver oral care training on stroke survivor oral and respiratory health in Taiwan: a randomised controlled trial.

    Community dental health·2015
    Same author

    A home-based training programme improves family caregivers' oral care practices with stroke survivors: a randomized controlled trial.

    International journal of dental hygiene·2015
    Same author

    Assessing the toxicity and associated costs among pediatric patients admitted with unintentional poisonings of attention-deficit/hyperactivity disorder drugs in the United States.

    Clinical toxicology (Philadelphia, Pa.)·2013
    Same author

    Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.

    Clinical pharmacology and therapeutics·2012
    Same author

    Lactation, lactation suppression hormones and breast cancer.

    Oncology reports·2011

    Area of Science:

    • Pharmacology
    • Gastroenterology

    Background:

    • Domperidone is a novel dopamine antagonist recently approved in Canada.
    • Unlike other dopamine antagonists, it exhibits limited central nervous system penetration.

    Purpose of the Study:

    • To review the pharmacologic properties, approved indications, and safety profile of domperidone.
    • To highlight its role in managing upper gastrointestinal motility disorders.
    • To discuss its utility in mitigating gastrointestinal symptoms associated with Parkinson's disease treatments.

    Main Methods:

    • Literature review of domperidone's pharmacology.
    • Analysis of clinical data regarding its efficacy and safety.
    • Examination of its approved uses in Canada.

    Main Results:

    • Domperidone functions as both an antiemetic and an upper gastrointestinal prokinetic agent.
    • Rapid oral absorption with a low incidence of reported side effects.
    • Approved for symptomatic treatment of upper gastrointestinal motility disorders.
    • Approved for preventing gastrointestinal symptoms in Parkinson's disease patients using dopamine agonists.

    Conclusions:

    • Domperidone offers a valuable therapeutic option for specific gastrointestinal conditions.
    • Its non-CNS penetrating profile may offer an advantage over other dopamine antagonists.
    • Further clinical experience will continue to define its role in patient care.

    Related Experiment Videos